High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1926-1934

  Oue, Naohide ^a,b   Anami, Katsuhiro ^a,b   Schetter, Aaron J ^a   Moehler, Markus ^c   Okayama, Hirokazu ^a   Khan, Mohammed A ^a   Bowman, Elise D ^a   Mueller, Annett ^c   Schad, Arno ^c   Shimomura, Manabu ^d   Hinoi, Takao ^d   Aoyagi, Kazuhiko ^e   Sasaki, Hiroki ^e   Okajima, Masazumi ^f   Ohdan, Hideki ^d   Galle, Peter R ^c   Yasui, Wataru ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

Author keywords

colorectal cancer; microRNA; prognosis

Indexed keywords

COLORECTAL CANCER; MICRORNA; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FORMALDEHYDE; HUMANS; MALE; MICRORNAS; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARAFFIN EMBEDDING; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893765780     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28522     Document Type: Article

References (49)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8. (Pubitemid 20042739)
2. Benson AB, III, Schrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19. (Pubitemid 41103700)
3. Grady WM, Carethers JM,. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-99.
4. Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489-99.
5. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24: 4685-91. (Pubitemid 46630932)
6. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009; 15: 5878-87.
7. Srinivasan M, Sedmak D, Jewell S,. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002; 161: 1961-71. (Pubitemid 35434840)
8. Specht K, Richter T, Muller U, et al. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419-29. (Pubitemid 32158605)
9. Huntzinger E, Izaurralde E,. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99-110.
10. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8. (Pubitemid 40839735)
11. Schetter AJ, Heegaard NH, Harris CC,. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49.
12. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61. (Pubitemid 43271657)
13. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98. (Pubitemid 43357945)
14. Saito M, Schetter AJ, Mollerup S, et al. The association of MicroRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011; 17: 1875-82.
15. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-36. (Pubitemid 351185951)
16. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010; 11: 136-46.
17. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009; 15: 6192-200.
18. Zhao Y, Schetter AJ, Yang GB, et al. microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 2012.
19. Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010; 64: 399-408.
20. Kulda V, Pesta M, Topolcan O, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 2010; 200: 154-60.
21. Nielsen BS, Jorgensen S, Fog JU, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28: 27-38.
22. Kjaer-Frifeldt S, Hansen TF, Nielsen BS, et al. The prognostic importance of miR-21 in stage II colon cancer: a population-based study. Br J Cancer 2012; 107: 1169-74.
23. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010; 70: 4528-38.
24. Hwang JH, Voortman J, Giovannetti E, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5: e10630.
25. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-60.
26. Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10: 507-17.
27. Avissar M, McClean MD, Kelsey KT, et al. MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 2009; 30: 2059-63.
28. Li J, Huang H, Sun L, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009; 15: 3998-4008.
29. Zhi F, Chen X, Wang S, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 2010; 46: 1640-9.
30. Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010; 116: 945-52.
31. Strauss WM,. Preparation of genomic DNA from mammalian tissue. Curr Protoc Mol Biol 2001.
32. Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57. (Pubitemid 28521189)
33. Laghi L, Malesci A,. Microsatellite instability and therapeutic consequences in colorectal cancer. Dig Dis 2012; 30: 304-9.
34. Garzon R, Marcucci G, Croce CM,. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
35. Schimanski CC, Frerichs K, Rahman F, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009; 15: 2089-96.
36. Iorio MV, Croce CM,. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-56.
37. Shibuya H, Iinuma H, Shimada R, et al. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313-20.
38. Krichevsky AM, Gabriely G,. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53.
39. Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 2010; 107: 21098-103.
40. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-94.
41. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007; 7: 36.
42. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-74. (Pubitemid 47481675)
43. Doleshal M, Magotra AA, Choudhury B, et al. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2008; 10: 203-11. (Pubitemid 351692162)
44. Zhang X, Chen J, Radcliffe T, et al. An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 2008; 10: 513-9.
45. Hui AB, Shi W, Boutros PC, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009; 89: 597-606.
46. Liu A, Tetzlaff MT, Vanbelle P, et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol 2009; 2: 519-27.
47. Siebolts U, Varnholt H, Drebber U, et al. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol 2009; 62: 84-8.
48. Andreasen D, Fog JU, Biggs W, et al. Improved microRNA quantification in total RNA from clinical samples. Methods 2010; 50: S6-9.
49. Goswami RS, Waldron L, Machado J, et al. Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnol 2010; 10: 47.